BioSpace News Archive

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (FSE: A2JMZC) (“Khiron” or the “Company”), announces that its wholly owned subsidiary ZereniaTM Colombia has closed an unsecured revolving credit facility of CAD 580,0001 with a private financing company in Colombia.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”) has announced a collaboration with the International Neurorehabilitation Institute (INI) (https://inirehab.com/) in Lutherville, Maryland to perform a clinical trial to assess the capacity of its RGC composition to promote eye health.

Canada Diagnostic Centres, a leading provider of medical imaging services, announces the strategic acquisitions of both Guardian Radiology and The Ultrasound Centre.

Select Medical announced a joint venture agreement with AtlantiCare to own and manage operations of a new inpatient rehabilitation hospital and 13 outpatient physical therapy centers throughout the southeastern region of New Jersey.

Madisonville Community College is one of 16 colleges that make up the Kentucky Community & Technical College System.

NANO-X IMAGING LTD, an innovative medical imaging technology company announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, has connected to the Nuance Precision Imaging Network™.

Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D., Ph.D. to its Board of Directors.

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, announced that it has received formal notice from The Nasdaq Stock Market, LLC, stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that Dr. Jose Avitia of the New Mexico Cancer Center will present updated data from the Company’s ongoing Phase 1/2a study of PRL-02 for the treatment of advanced prostate cancer on Thursday Feb 16 from 11:30AM to 1:00PM PST at the 2023 ASCO Genitourinary (GU) Cancers Symposium.